STOCKHOLM, Nov. 15, 2018
STOCKHOLM, Nov. 15, 2018 /PRNewswire/ --
Cantargia AB's interim report for the third quarter of 2018 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the third quarter
Change of list
Significant events after the end of the period
First nine months (1 Jan 2018 – 30 Sep 2018)
Third quarter (1 July 2018 – 30 Sep 2018)
For further information, please contact
Göran Forsberg, CEO
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 15 2018.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop a IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Pressmeddelande-delarsrapport eng final